Jazz Pharmaceuticals (Italy)

Recent papers from Jazz Pharmaceuticals (Italy)

1. Machine learning classification of fibromyalgia from blood transcriptomes: confounder benchmarking and implications for endometriosis-associated pain2026
2. Social Determinants of Health, Clinical Outcomes, and Healthcare Resource Utilization in Participants With and Without Narcolepsy in the All of Us Research ProgramSLEEP Advances · 2026
3. Liposomes versus Sphingosomes: Microfluidic DoE-Guided development of lipid nanocarriers for the delivery of a synthetic hMAO inhibitorInternational Journal of Pharmaceutics · 2026
4. Co-Creation of the EpiCom Clinical Trial: Bringing the Tuberous Sclerosis Complex Patient Community, Healthcare Professionals, and the Pharmaceutical Industry TogetherPatient · 2026
5. CPX‑351 vs. FLAG‑ida in patients with high-risk AML/MDS and MDS-related gene mutations: a subgroup analysis of the UK NCRI AML19 trialLeukemia & lymphoma/Leukemia and lymphoma · 2026
6. Deciding to fight, regulating investment: hierarchical territorial defence in the Lanner falconEthology Ecology & Evolution · 2026
7. Efficacy of Citicoline as an add-on therapy in Parkinson’s disease: a randomized, double-blind trial.Parkinsonism & Related Disorders · 2026
8. Demographics and Clinical Factors Associated with Persistence on Cannabidiol in US Patients with Lennox-Gastaut Syndrome (LGS), Dravet Syndrome (DS), Tuberous Sclerosis Complex (TSC), or Other Refractory Epilepsies (P10-10.004)Neurology · 2026
9. Tuberous Sclerosis Complex (TSC)–Associated Neuropsychiatric Disorders (TAND) Outcomes Following Adjunctive Cannabidiol (CBD) Treatment: 6-Month Intermediate Analysis of the EpiCom Trial (S5.005)Neurology · 2026
10. Cannabidiol Efficacy in Patients with Lennox-Gastaut Syndrome with Developmental and Epileptic Encephalopathy-associated Genetic Variants: A Subgroup Analysis (P10-10.008)Neurology · 2026
11. An Assessment of Acute Pharmacodynamic Drug-drug Interactions (PD-DDIs) Between Cannabidiol (CBD) and Cenobamate (CNB) in a Mouse Model of Generalized Tonic Seizures (P3-10.001)Neurology · 2026
12. Molecular circulating tumor DNA (ctDNA) profiling from patients (pts) treated with zanidatamab + chemotherapy (CT) in first-line (1L) HER2-positive (HER2+) advanced or metastatic gastroesophageal adenocarcinoma (mGEA).Journal of Clinical Oncology · 2026
13. C21-02 Safety of Low-Sodium Oxybate in Participants With Narcolepsy or Idiopathic Hypersomnia, With or Without Comorbid Obstructive Sleep Apnea: A Post Hoc Analysis of the Duet StudyAmerican Journal of Respiratory and Critical Care Medicine · 2026
14. A double-blind, randomized, multicenter, phase 2b study of the safety and efficacy of suvecaltamide in essential tremorParkinsonism & Related Disorders · 2026
15. The maturing picture of CPX-351 in acute myeloid leukemia: long-term real-world experience with CPX-351 treatment for acute myeloid leukemia in EnglandLeukemia & lymphoma/Leukemia and lymphoma · 2026
16. Physiological and cortical determinants of exercise tolerance in sedentary women with obesityFrontiers in Sports and Active Living · 2026
17. Zanidatamab, a Dual HER2-Targeted Bispecific Antibody, in Patients With Unresectable Locally Advanced or Metastatic HER2-Positive Salivary Gland Cancer: A Combined Analysis of Early-Phase StudiesClinical Cancer Research · 2026
18. 429P Real-world (RW) effectiveness and safety of lurbinectedin for previously treated small cell lung cancer (SCLC): Jazz EMERGE 402ESMO Open · 2026
19. Smart Microfluidics: a curated dataset of microfluidic liposome formulations with cross-laboratory validation for machine-learning applicationsData in Brief · 2026
20. AI-guided mechanistic insights and optimization of heavy metal removal from industrial effluents using bioengineered chitosanProcess Safety and Environmental Protection · 2026